Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies.
Acute Kidney Injury
/ chemically induced
Adolescent
Adult
Aged
Aged, 80 and over
Antimetabolites, Antineoplastic
/ adverse effects
Female
Follow-Up Studies
Hematologic Neoplasms
/ drug therapy
Humans
Male
Methotrexate
/ adverse effects
Middle Aged
Prognosis
Retrospective Studies
Risk Factors
Survival Rate
Young Adult
acute kidney injury
albumin
lactic dehydrogenase
methotrexate
survival
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
30
10
2019
revised:
12
05
2020
accepted:
26
05
2020
pubmed:
9
6
2020
medline:
3
11
2020
entrez:
8
6
2020
Statut:
ppublish
Résumé
High dose methotrexate (HDMTX)-induced acute kidney injury (AKI) is a well-known adverse event in hemato-oncology patients. Our purpose was to define factors and setup cut-offs that may help better identify patients at-risk for developing AKI following HDMTX. All consecutive patients who received MTX dose ≥1 g were retrospectively reviewed. We compared patients with or without renal toxicity. We used a logistic regression model to define baseline variables associated with AKI. Overall survival (OS) was estimated by the Kaplan-Meier method employing log-rank test. Between 2012 and 2017, 160 patients were included with a total of 265 courses. Indications included: primary central nervous system (CNS) lymphoma, CNS prophylaxis in other lymphoma types, acute lymphatic leukemia and others. Median age at diagnosis was 58 years (range, 18-84), 54% were males, median MTX dose was 1941 mg/m
Substances chimiques
Antimetabolites, Antineoplastic
0
Methotrexate
YL5FZ2Y5U1
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
584-588Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Treon SP, Chabner BA. Concepts in use of high-dose methotrexate therapy. Clin Chem. 1996;42:1322-1329.
Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11(6):694-703.
Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471-1482.
Perazella MA, Luciano RL. Review of select causes of drug-induced AKI. Expert Rev Clin Pharmacol. 2015;8(4):367-371.
Garneau AP, Riopel J, Isenring P. Acute methotrexate-induced crystal nephropathy. N Engl J Med. 201531;373(27):2691-2693.
Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med. 1977;297(12):630-634.
Relling MV, Fairclough D, Ayers D, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol. 1994;12:1667-1672.
Ferreri AJM, Guerra E, Regazzi M, et al. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer. 2004;90:353-358.
Green MR, Chamberlain MC. Renal dysfunction during and after high-dose methotrexate. Cancer Chemother Pharmacol. 2009;63:599-604.
de Miguel D, García-Suárez J, Martín Y, et al. Severe acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: a significant number result from unrecognized co-administration of several drugs. Nephrol Dial Transplant. 2008;23:3762-3766.
Dalle J-H, Auvrignon A, Vassal G, Leverger G. Interaction between methotrexate and ciprofloxacin. J Pediatr Hematol Oncol. 2002;24:321-322.
Widemann BC, Balis FM, Kempf-Bielack B, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer. 2004;100:2222-2232.
Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03; 2010. http://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-0614_QuickReference_5x7.pdf. Accessed April 4, 2010.
May J, Carson KR, Butler S, Liu W, Bartlett NL, Wagner-Johnston ND. High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective. Leuk Lymphoma. 2014;55(6):1345-1349.
Wiczer T, Dotson E, Tuten A, Phillips G, Maddocks K. Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity. J Oncol Pharm Pract. 2016;22(3):430-436.
Ramsey LB, Panetta JC, Smith C, et al. Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood. 2013;121:898-904.
Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120:c179-c184.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
Jahnke K, Korfel A, Martus P, et al. High dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol. 2005;16(3):445-449.
Kawakatsu S, Nikanjam M, Lin M, et al. Population pharmacokinetic analysis of high dose methotrexate in pediatric and adult oncology patients. Cancer Chemother Pharmacol. 2019;84:1339-1348.
Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:2373-2380.
Nooka AK, Nabhan C, Zhou X, et al. Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol. 2013;24:441-448.
Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863-2869.
Zager RA, Johnson ACM, Becker K. Renal cortical lactate dehydrogenase: a useful, accurate, quantitative marker of in vivo tubular injury and acute renal failure. PLoS One. 2013;8(6):e66776.
Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, et al. Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. Am J Hematol. 2012;87:1006-1009.
Bairey O, Shacham-Abulafia A, Shpilberg O, Gurion R. Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor. Hematol Oncol. 2016;34(4):184-192.
Reiss S, Buie L, Adel N, et al. Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia. Ann Hematol. 2016;95:2009-2015.
Lotan E, Leader A, Lishner M, Gottfried M, Pereg D. Unrecognized renal insufficiency and chemotherapy-associated adverse effects among breast cancer patients. Anticancer Drugs. 2012;23(9):991-995.
Strati P, Chaffee KG, Achenbach SJ, et al. Renal insufficiency is an independent prognostic factor in patients with chronic lymphocytic leukemia. Haematologica. 2017;102(1):e22-e25.
Chng WJ, Dispenzieri A, Chim CS, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28(2):269-277.